Login to Your Account

Wilex Delays Raising €14M After Good Data on Antibody

By Cormac Sheridan

Wednesday, December 2, 2009

No Abstract


BioWorld International Correspondent

Wilex AG delayed completion of a capital increase because of the early arrival of positive preliminary data from a Phase III trial of its diagnostic antibody Redectane, which is in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription